CurrentColorado Rocky Mountain Health PlansPolicy IEXD0054.07

Off-Label/Unproven Specialty Drug Treatment – Individual Exchange Medical Benefit Drug Policy

Defines coverage parameters for off-label and unproven indications of FDA-approved specialty drugs under the Individual Exchange medical benefit (excludes MA, NV, NY). Excludes pharmacy-benefit self-administered meds, oncology per NCCN, and vaccines.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOff-Label/Unproven Specialty Drug Treatment – Individual Exchange Medical Benefit Drug Policy

Policy CodePolicy IEXD0054.07

Change TypeDefinitions and Coverage Rationale updated (08/01/2025)

Effective DateAug 1, 2025

Next Review Date

Key ActionProvide documentation showing all policy criteria are met and supply supporting evidence from AHFS‑DI, Clinical Pharmacology, DRUGDEX, InterQual Specialty Rx, or two peer‑reviewed journal articles.

SourceLink

POLICY UPDATE CHANGES

Coverage Rationale modification on 08/01/2025: removed prior limitation about case studies/series not meeting peer-reviewed article standard.

Definitions updated on 08/01/2025: 'Serious Rare Disease' definition revised.

Supporting information and references updated on 08/01/2025; previous policy version IEXD0054.06 archived.

1Applies to Individual Exchange plans (excl. MA, NV, NY)

8Evidence sources listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Material policy changes on 08/01/2025

Coverage Summary

This policy defines off-label/unlabeled use under the medical benefit for FDA‑approved specialty drugs and sets coverage parameters for off-label and unproven indications for Individual Exchange benefit plans (applies to all states except Massachusetts, Nevada, and New York). It applies to provider‑administered or supervised specialty drugs and patient self‑administered specialty drugs when covered under the medical benefit and when a UnitedHealthcare policy does not address the requested indication or lists the drug as unproven. Key exclusions include self‑administered medications covered under the pharmacy benefit, oncology medications covered under the NCCN Drugs & Biologics Compendium, and vaccines.

Policy numberIEXD0054.07

Effective dateAugust 1, 2025

Last reviewAugust 1, 2025

StatusCURRENT

SubjectOff-Label/Unproven Specialty Drug Treatment

Scope summaryDefines coverage parameters for off-label and unproven indications of FDA-approved specialty drugs under the Individual Exchange medical benefit (excludes MA, NV, NY). Excludes pharmacy-benefit self-administered meds, oncology per NCCN, and vaccines.

Indications of Coverage (medically necessary for off-label/unproven indication)

A specialty drug may be determined medically necessary for the requested off-label or unproven indication when ALL of the criteria are met:

ALL of the following

The drug is approved by the U.S. Food and Drug Administration
The requested drug has not been excluded from coverage by UnitedHealthcare due to lack of efficacy, clinical benefit, or administrative program (e.g., exclusion at launch, plan document)
One of the following
- The requested drug is considered 'unproven' per UnitedHealthcare drug policy, where applicable

Provider Actions & Prior Authorization

Prior Authorization

Prior authorization requirement

Coverage determinations for off‑label or unproven specialty drug indications require prior authorization. Submit documentation that ALL policy criteria are met: the drug is FDA‑approved; the drug has not been excluded from UnitedHealthcare coverage; the drug is intended to treat a chronic and seriously debilitating condition or a Serious Rare Disease; the patient has not previously failed the same drug; the patient is not enrolled in an eligible clinical trial; documented history of failure, contraindication, or intolerance to standard/conventional therapies (where available); and clinical support from compendia or literature (see accepted sources).

FDA approval for the requested indication
Requested drug is not excluded from UnitedHealthcare coverage
Drug intended for a chronic and seriously debilitating condition or a Serious Rare Disease
No prior failure of the same drug
Patient is not currently in an eligible clinical trial
Documented failure, contraindication, or intolerance to standard/conventional therapies, where available
Clinical support from at least one accepted compendium or evidence source (AHFS‑DI, Clinical Pharmacology, DRUGDEX Class I/IIa/IIb, InterQual Specialty Rx, or two peer‑reviewed journal articles)

Applicable Codes & Identifiers

Policy identifiermixed

IEXD0054.07

UnitedHealthcare Medical Benefit Drug Policy Number

Definitions

Serious Rare Disease: A clinical condition that is serious (life‑threatening or accompanied by significant major disability or imminent threat of major disability) and rare (affects fewer than 200,000 people in the U.S. at any given time).

Off‑label/unlabeled use: Use of a drug for a non‑FDA approved indication or in a way that deviates significantly from labeled prescribing information.

Compendium: A comprehensive listing of FDA‑approved drugs and biologicals or a comprehensive listing of a specific subset of drugs and biologicals in a specialty compendium.

Clinical Evidence & Evidence Sources

Determinations of medical necessity for off‑label uses rely on scientific evidence and accepted compendia. The policy requires clinical indications to be supported by at least one accepted source: AHFS‑DI, Clinical Pharmacology, DRUGDEX (with an appropriate Strength of Recommendation rating), InterQual Specialty Rx, or two articles from major peer‑reviewed medical journals demonstrating the off‑label use is generally safe and effective (unless there is validated and uncontested contradictory evidence).

Accepted evidence for diagnosis supportAHFS-DI (Therapeutic Uses), Clinical Pharmacology (Indications), DRUGDEX (Strength of Recommendation Class I/IIa/IIb under Therapeutic Uses), InterQual Specialty Rx, or two peer-reviewed articles from major journals

Evidence sources listed8 (AHFS-DI, Clinical Pharmacology, DRUGDEX, InterQual, peer-reviewed literature, FDA, CDC, NIH, GRADE)

Background & Scope

This policy defines off‑label/unlabeled use and the scope for specialty drugs under the medical benefit, clarifies exclusions (pharmacy‑benefit self‑administered medications, oncology medications referenced to the NCCN Compendium, and vaccines), and specifies how compendia and peer‑reviewed evidence are used to support medical necessity. The policy applies to Individual Exchange plans except for Massachusetts, Nevada, and New York and covers provider‑administered or supervised specialty drugs and patient self‑administered specialty drugs when they are covered under the medical benefit and the requested indication is not addressed or is listed as unproven by a UnitedHealthcare drug policy.

Revision History

2025-08-01Coverage Rationale modificationLatest

Removed notation indicating evidence limited to case studies or case series is not sufficient to meet the standard for peer-reviewed articles presented in a major peer-reviewed medical journal. (Summary of Changes: Coverage Rationale updated.)

2025-08-01Definitions updateLatest

Updated definition of 'Serious Rare Disease' to specify seriousness (life threatening or accompanied by significant major disability or imminent threat of major disability) and rarity (affects fewer than 200,000 people in the U.S. at any given time).

Operational Notes

Operationally, coverage decisions rely on verification that all policy criteria are met and that the diagnosis is supported by at least one accepted compendium or the specified peer‑reviewed literature; prior authorization reviewers must document FDA approval, that the drug is not excluded by UnitedHealthcare, intended use for a chronic/serious or Serious Rare Disease, absence of prior failure of the same drug, patient not enrolled in an eligible clinical trial, documented failure/contraindication/intolerance to standard therapies where available, and supportive compendia or literature. The policy history notes a material coverage rationale change effective 08/01/2025 but does not provide separate Medicare determinations in this brief.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOff-Label/Unproven Specialty Drug Treatment – Individual Exchange Medical Benefit Drug Policy

Policy CodePolicy IEXD0054.07

Change TypeDefinitions and Coverage Rationale updated (08/01/2025)

Effective DateAug 1, 2025

Next Review Date

SourceLink

On This Page

The indication for the requested drug is not addressed by a UnitedHealthcare drug policy, where applicable

A UnitedHealthcare drug policy does not exist for the requested drug

The requested drug is intended to treat a chronic and seriously debilitating, or Serious Rare Disease

The patient has not failed a previous course or trial of the requested drug

The patient is not currently in an eligible clinical trial

Documented history of failure, contraindication, or intolerance to standard, conventional therapies to treat or manage the disease or condition, where available

Diagnosis is clinically supported by at least one of the following compendia or evidence sources

American Hospital Formulary Service Drug Information (AHFS-DI) under the Therapeutic Uses section
Elsevier Gold Standard's Clinical Pharmacology under the Indications section
DRUGDEX System by Micromedex has a Strength of Recommendation rating of Class I, Class IIa, or Class IIb under the Therapeutic Uses section
Clinical indications supported by InterQual Specialty Rx
Two (2) articles from major peer reviewed medical journals that present data supporting the proposed off-label use or uses as generally safe and effective unless there is validated and uncontested contradictory evidence presented in a major peer-reviewed medical journal

Documentation Required

Clinical support documentation

Clinical support documentation must be provided to demonstrate the off‑label indication is clinically supported. Acceptable supportive evidence includes citations from AHFS‑DI, Clinical Pharmacology, DRUGDEX, InterQual Specialty Rx, or two articles from major peer‑reviewed medical journals that present data supporting the proposed off‑label use as generally safe and effective (unless there is validated and uncontested contradictory evidence).

Accepted compendia: AHFS‑DI (Therapeutic Uses), Clinical Pharmacology (Indications), DRUGDEX (Strength of Recommendation Class I, IIa, or IIb), InterQual Specialty Rx
Alternatively, two (2) articles from major peer‑reviewed medical journals (e.g., JAMA, NEJM, Lancet) presenting supportive data for the off‑label use

2025-08-01Supporting information/references updateLatest

Updated References section to reflect the most current information and archived previous policy version IEXD0054.06. (Non-material change to supporting information and references.)

2025-08-01Policy effective dateLatest

Policy IEXD0054.07 effective date recorded as August 1, 2025.